In a nutshell This study evaluated the effectiveness and safety of venetoclax (Venclexta) monotherapy (single-agent treatment) in patients with relapsed (cancer recurrence) or refractory (does not respond to initial treatment) mantle cell lymphoma (MCL). This study concluded that venetoclax monotherapy is promising, with minimal side effects. Some...
Read More
In a nutshell This study looked at the risk of infections associated with ibrutinib (Imbruvica) used in the treatment of leukemia and lymphoma. Researchers found that patients receiving ibrutinib are at risk of serious infections. Some background Ibrutinib is a drug which targets certain proteins on cancer cells to stop them from working. It is often...
Read More
In a nutshell This study evaluated the effectiveness and safety of the R-CyBorD (rituximab, cyclophosphamide, bortezomib, dexamethasone) regimen in patients with relapsed indolent (painless) non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen is effective and well-tolerated in these patients. Some background There are many...
Read More
In a nutshell This article reviewed current and new treatment options for patients with mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is a rare but aggressive type of non-Hodgkin’s lymphoma. Chemoimmunotherapy is the typical first-line (primary) treatment for MCL. 80 – 90% of patients respond to this treatment. However,...
Read More
“Always trust your gut. Don’t leave your treatment in the hands of someone that you don’t trust or that does not seem like a team player. Yes, they are all smart—even brilliant—but read, read, read, and question them at every corner and challenge the standard of care. Exercise, healthy eating, learning the ropes of insurance, mediation/prayer...
Read More
In a nutshell This article reviewed different treatment options for patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) mantle cell lymphoma (MCL). Some background Chemoimmunotherapy is the typical first-line (primary) treatment for patients with MCL. 80 – 90% of patients respond to treatment, but many...
Read More
In a nutshell This study investigated the effectiveness of autologous stem cell transplantation (autoSCT) for patients with follicular lymphoma who experienced early treatment failure (ETF; relapse or disease progression within 2 years after first-line therapy). This study concluded that autoSCT may be an effective option for these patients. Some...
Read More
In a nutshell This article reviewed the use of proton therapy in adult patients with lymphoma in the mediastinum (the middle section of the chest around the lungs). Some background Many lymphomas are found in the mediastinum, next to the heart, lungs, and breasts. These organs are especially sensitive to chemotherapy and radiation therapy. In adult...
Read More
In a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...
Read More
In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) maintenance therapy in patients with newly diagnosed follicular lymphoma (FL). This study concluded that this therapy improves survival outcomes in these patients. Some background For patients with early (stage 1 – 2) FL, aggressive radiotherapy or...
Read More
In a nutshell This study evaluated the safety and effectiveness of the BR regimen (rituximab, bendamustine) in elderly patients with untreated low-tumor burden follicular lymphoma (LTBFL). This study concluded that the BR regimen may provide positive outcomes for these patients. Some background Low-tumor burden follicular lymphoma (LTBFL) is a type of...
Read More
In a nutshell This study evaluated the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) development in patients with lymphoma and myeloma after an autologous stem cell transplant (autoSCT). This study concluded that this risk is quite high after autoSCT in these patients. Some background AML and MDS are known long-term...
Read More
